Fig. 1From: Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort studyPatient selection flow chart. CGRD Chang Gung Research DatabaseBack to article page